MRK catalyst calendar

Merck & Co., Inc.

Upcoming catalysts
22
Cash runway
Cash generating
Cash & investments
$7141M
Phase 3 programs
38

Merck & Co., Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 8, 2026, a projected date rather than a confirmed one. There are 22 upcoming events on record.

Merck & Co., Inc. generates cash from operations, so a burn-based runway figure does not apply.

Across 274 concluded trials, 81% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 8, 2026 est. Next quarterly earnings (projected) Earnings —
February 9, 2027 A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012) Trial Milestone Phase 1
February 12, 2027 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) Trial Milestone Phase 2
March 22, 2027 Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Trial Milestone Phase 2
July 14, 2027 A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) Trial Milestone Phase 3
October 12, 2027 A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) Trial Milestone Phase 2
December 18, 2027 A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108) Trial Milestone Phase 3
January 8, 2028 A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). Trial Milestone Phase 2
January 25, 2028 Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) Trial Milestone Phase 3
November 8, 2028 A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) Trial Milestone Phase 2
November 12, 2028 Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) Trial Milestone Phase 2
February 19, 2029 Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) Trial Milestone Phase 3
March 28, 2029 A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) Trial Milestone Phase 3
May 17, 2029 A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) Trial Milestone Phase 2
May 24, 2029 A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032) Trial Milestone Phase 2
July 27, 2029 A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) Trial Milestone Phase 3
September 24, 2029 DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg Trial Milestone Phase 2
November 27, 2030 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) Trial Milestone Phase 3
March 7, 2031 A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) Trial Milestone Phase 1/Phase 2
May 24, 2032 A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) Trial Milestone Phase 3
November 18, 2032 Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) Trial Milestone Phase 2
May 16, 2033 A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) Trial Milestone Phase 3

Track MRK alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open MRK in the tracker

Recent history

DateEventTypePhase
October 14, 2026 A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039) Trial Milestone Phase 1
October 13, 2026 8-K filed: Leadership change Corporate —
September 28, 2026 A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005) Trial Milestone Phase 1
August 4, 2026 Quarterly results filed (8-K) Earnings —
August 3, 2026 A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) Trial Milestone Phase 3
August 3, 2026 A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) Trial Milestone Phase 2
June 13, 2026 A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) Trial Milestone Phase 1
May 22, 2026 8-K filed: Other event Filing —
April 30, 2026 Quarterly results filed (8-K) Earnings —
April 11, 2026 A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) Trial Milestone Phase 1
April 9, 2026 A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012) Trial Milestone Phase 1
February 17, 2026 A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023) Trial Milestone Phase 1
February 4, 2026 A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study Trial Milestone Phase 3
February 3, 2026 Quarterly results filed (8-K) Earnings —
December 22, 2025 V114 and Acute Otitis Media (V114-032/PNEU-ERA) Trial Milestone Phase 3
December 4, 2025 8-K filed: Other event Filing —
October 30, 2025 Quarterly results filed (8-K) Earnings —
October 17, 2025 Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) Trial Milestone Phase 1/Phase 2
October 17, 2025 A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001) Trial Milestone Phase 1
September 9, 2025 8-K filed: Other event Filing —
August 8, 2025 A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005) Trial Milestone Phase 1
July 29, 2025 Quarterly results filed (8-K) Earnings —
July 14, 2025 A Study of MK-2225 in Healthy Participants (MK-2225-003) Trial Milestone Phase 1
July 3, 2025 A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002) Trial Milestone Phase 1
June 5, 2025 A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants Trial Milestone Phase 1
May 16, 2025 A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035) Trial Milestone Phase 1
April 24, 2025 Quarterly results filed (8-K) Earnings —
April 18, 2025 A Study of MK-2060 in Healthy Participants (MK-2060-016) Trial Milestone Phase 1
April 11, 2025 Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059) Trial Milestone Phase 3
April 9, 2025 A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.